SCHEMBL21361939

SCHEMBL21361939

COC(=O)c1cc(-c2ccccc2Cl)on1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.65
RAB9A P51151 7/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
NOTUM Q6P988 2/20 0.62
KLF5 Q13887 1/20 0.58
HCRTR1 O43613 1/20 0.57
HPGD P15428 4/20 0.55
ALDH1A1 P00352 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP3A4 P08684 1/20 0.55
MAPT P10636 2/20 0.54
TP53 P04637 1/20 0.54
MAPK1 P28482 1/20 0.51
NPY1R P25929 1/20 0.51
NPY2R P49146 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258916 0.84 MAPT (0.59) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL6818530 0.84 MAPT (0.55) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL22908292 0.83 NPC1 (0.62) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL6818243 0.82 MAPT (0.54) NPC1RAB9AMEN1KMT2ANOTUM
SCHEMBL3413937 0.81 NPC1 (0.63) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL22862244 0.79 NPC1 (0.61) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL6822322 0.79 NOTUM (0.60) NPC1RAB9AMEN1KMT2ANOTUM
SCHEMBL69157 0.78 MAPT (0.72) NPC1RAB9AMEN1KMT2ANOTUM
SCHEMBL21361937 0.77 HPGD (0.70) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL21777026 0.77 NOTUM (1.00) NPC1RAB9AL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091450-B2 Crystal of a caspase inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-08-17 US disclosed
EP-3766873-A1 METHOD FOR PREPARING CASPASE INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-01-20 EP disclosed
US-20210002235-A1 A CRYSTAL OF A CASPASE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-01-07 US disclosed
WO-2019174589-A1 METHOD FOR PREPARING CASPASE INHIBITOR 正大天晴药业集团股份有限公司 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002235-A1 A CRYSTAL OF A CASPASE INHIBITOR CASP1, CASP7, CASP14 NPC1 2675/4885RAB9A 4344/4885L3MBTL1 3289/4885
US-11091450-B2 Crystal of a caspase inhibitor CASP1, CASP14, CASP7 NPC1 2920/4885RAB9A 4477/4885L3MBTL1 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.